Pulmatrix presents iCALM clinical study results
The study concluded that iCALM is a novel inhaled therapeutic with a previously unexplored mechanism of action that can lead to better control of symptoms and lung function
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.